Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

3.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
3.4K
Drug Biotransformation: Overview01:28

Drug Biotransformation: Overview

2.3K
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
2.3K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

18.2K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.2K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.6K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.6K
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

148
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
148
Experimental RNAi02:15

Experimental RNAi

7.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Translational and clinical development of therapeutic siRNA and ASOs: current industry practices, perspectives, and recommendations.

Nucleic acids research·2025
Same author

Use of a Transgenic Human PNPLA3<sup>I148M</sup> Knock-in Mouse for Translational Safety Evaluations of siRNA Therapeutics.

Nucleic acid therapeutics·2025
Same author

A double-blind, controlled trial of circadian effective light therapy in patients with Parkinson's disease.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2025
Same author

Real-time single-element-detection structured illumination optical metrology for laser powder bed fusion.

Optics express·2025
Same author

Invited Session II: Visual Prosthetics: The Neuralink Implant as a visual prosthesis.

Journal of vision·2025
Same author

Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier.

Science translational medicine·2024

Related Experiment Video

Updated: Dec 22, 2025

Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

11.4K

Emerging siRNA Design Principles and Consequences for Biotransformation and Disposition in Drug Development.

Sara C Humphreys1, Mai B Thayer1, Jabbar Campbell2

  • 1Pharmacokinetics and Drug Metabolism Department, Amgen Research, 1120 Veterans Boulevard, South San Francisco, California 94080, United States.

Journal of Medicinal Chemistry
|May 1, 2020
PubMed
Summary
This summary is machine-generated.

This study highlights the need for better understanding of siRNA Absorption, Distribution, Metabolism, and Excretion (ADME) properties. Improved ADME knowledge is crucial for advancing siRNA drug development and ensuring safety.

More Related Videos

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

7.8K
MISSION esiRNA for RNAi Screening in Mammalian Cells
15:31

MISSION esiRNA for RNAi Screening in Mammalian Cells

Published on: May 12, 2010

16.7K

Related Experiment Videos

Last Updated: Dec 22, 2025

Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

11.4K
Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

7.8K
MISSION esiRNA for RNAi Screening in Mammalian Cells
15:31

MISSION esiRNA for RNAi Screening in Mammalian Cells

Published on: May 12, 2010

16.7K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Drug Development

Background:

  • Small interfering RNA (siRNA) therapeutics have progressed from laboratory tools to approved drugs.
  • Early development focused on efficacy and safety, leading to a gap in understanding siRNA ADME properties.

Purpose of the Study:

  • To address the lack of comprehensive siRNA ADME data.
  • To propose a framework for evaluating siRNA ADME to optimize drug discovery and translation.
  • To discuss safety, regulatory aspects, and future directions for siRNA therapeutics.

Main Methods:

  • Review of emerging siRNA design principles and their impact on disposition.
  • Conceptual framework for siRNA ADME evaluation.
  • Discussion of biotransformation, PK-PD relationships, and safety.

Main Results:

  • Emerging siRNA design principles influence disposition and biotransformation.
  • A structured approach to ADME evaluation is proposed.
  • Contextualizing biotransformation with PK-PD modulation is key.

Conclusions:

  • Advancing siRNA ADME knowledge is essential for establishing in vitro-in vivo correlations and PK-PD relationships.
  • Optimizing candidate selection requires a deeper understanding of ADME.
  • Further research into safety and regulatory considerations is needed for this therapeutic modality.